Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humanized Anti-CD25 Antibody for aGVHD Prophylaxis in Elderly HID-HSCT
NCT05923814Phase 2Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2023
- Primary completion
- May 2024
01
Overview
Phase 2, open-label, single-arm trial in graft-versus-host disease (GVHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of acute Graft-versus-Host Disease at 24 weeks. Status: unknown.
02
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05923814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923814.